AI Fund

AI Fund is Andrew Ng’s venture studio, and that single fact is the most important context for any founder considering an approach. Based in Palo Alto with roughly $370M in cumulative capital, the firm operates as a startup studio rather than a conventional venture fund. AI Fund builds companies around AI applications, with healthcare among its active verticals alongside education, finance, and industrial automation. Check sizes run from $1M to $5M at pre-seed and seed, but the more meaningful resource is the studio’s hands-on company-building infrastructure: a deep bench of AI engineers, product managers, and operators who work alongside founding teams during the formation phase. For healthcare founders building AI-native products, AI Fund offers a path to capital, technical depth, and Andrew Ng’s reputational halo, with the trade-off that the studio model implies a different founder relationship than a standard venture deal.

The stated focus is AI/ML in healthcare specifically, with the broader AI Fund portfolio spanning multiple verticals where AI applications can create category-defining companies. The implied target healthcare company is one where the AI capability is core to the product hypothesis rather than a feature added to a traditional workflow tool. That includes AI-driven clinical decision support, medical imaging applications, drug discovery platforms, clinical operations automation, and AI-native consumer health products. Companies where AI is incidental are unlikely to fit. The studio model means AI Fund is often involved at the absolute beginning of a company’s life, sometimes recruiting founding teams around an internal thesis rather than backing existing teams. Founders should clarify early in conversation whether their company would be a studio-built or studio-backed deal, since the equity, governance, and operating implications differ substantially.

The firm’s broader portfolio is dominated by AI applications across multiple verticals, with healthcare positions including clinical and consumer-facing products. Specific healthcare portfolio names are not enumerated in the structured record, so founders should review the AI Fund portfolio page directly and read recent announcements. Patterns to watch for include companies leveraging foundation models for medical reasoning, companies using AI to compress drug discovery timelines, and consumer-facing health products built on conversational AI. The firm’s positioning means it is more likely to back AI-first healthcare bets than healthcare-first companies adding AI as a feature.

Check size at $1M to $5M places AI Fund as a meaningful pre-seed or seed participant, often as a lead or co-lead at the formation stage. With $370M total capital, the firm has reserves for meaningful follow-on into companies that achieve early traction. Co-investors at later rounds tend to include AI-focused funds, large multi-stage firms with AI thesis exposure, and selectively healthcare specialists when the company moves into clinical or regulated territory. Founders should expect that AI Fund’s involvement signals to downstream investors that the AI thesis has been validated by Andrew Ng’s team, which is a meaningful credentialing effect.

Decision-making concentrates around Andrew Ng and the studio’s senior partners. While the structured record does not enumerate the current team specifically, founders should research the firm’s leadership via the website and target the partner or principal whose thesis area aligns most closely with their company. Ng himself remains involved in major investment decisions and in studio-built company formations, with substantial day-to-day operations handled by the broader team. First contact is typically a partner or principal, with Ng engagement reserved for later-stage diligence.

Warm intros from AI Fund alumni, from Ng’s broader network including DeepLearning.AI, Coursera, and Stanford-affiliated researchers, and from co-investors in prior portfolio companies carry strong signal. Ng is unusually public for an investor of his profile, with extensive writing, the DeepLearning.AI newsletter, frequent podcast appearances, and a substantial Twitter and LinkedIn following. Founders can use his public commentary to calibrate which AI applications are currently top-of-mind for the studio. Cold inbound through the firm’s website is plausible for AI-native founders with strong technical backgrounds, but the bar is high.

Approach AI Fund when your healthcare company is genuinely AI-native at its core and when you are open to the studio model of founder support. Do not approach for healthcare companies where AI is a secondary feature, for therapeutics or device companies without significant AI components, or for late-stage rounds. Among portfolio founders, the firm has a reputation for technical depth and for high engagement during the formation phase, with the trade-off that the studio model can feel more directive than standard venture relationships. For founders genuinely committed to building AI-first healthcare companies, the combination of Ng’s network, the studio’s technical infrastructure, and the firm’s capital is among the more differentiated offerings in early-stage AI healthcare.